Is Galmed Pharmaceuticals Ltd. (GLMD) a Buy, Sell, or Hold?
Galmed Pharmaceuticals Ltd.
NASDAQ:GLMD
$0.5135 USD
$0.0 (0.43%)
- Volume
- 20.08K
- Average Volume
- 544.06K
- Market Capitalization
- $2.81M
- P/E Ratio
- -0.26
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $2.34
- Year Low
- $0.41
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.71
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Allen Baharaff |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GLMD |
| CUSIP | M4R16S102 |
| CIK | 0001595353 |
| Web | https://galmedpharma.com |
| Phone | 972 3 693 8448 |
| Currency | USD |
| Employees | 6 |
| Country | IL |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.71 |
| Quick Ratio | 7.71 |
| Cash Ratio | 0.77 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.17 |
| Price / Cash Flow | -0.37 |
| Price / Book | 0.24 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 16 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.39 |
| Trailing P/E Ratio | -0.26 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-10.31M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -64.10% |
| Return on Assets | -69.35% |
Financials Score
| AltmanZ Score | -19.00 |
| Piotroski Score | 1.00 |
| Working Capital | 13.95M |
| Total Assets | 16.03M |
| Ebit | -11.25M |
| Market Cap | 2.94M |
| Total Liabilities | 2.08M |
Poll Results
About Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Stock
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and ... fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.
2026-06-22 07:00:00
Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd.
2026-06-08 08:10:00
Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs. Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and Israel.
2026-06-02 07:30:00
- Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using a human cardiac organoid model, revealing disease biology that is not accessible through conventional animal models. - In inflammatory human cardiac organoids, the combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately 4-fold (p
2026-05-14 07:30:00
Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidification and prolongation of Aramchol's IP protection Potential reduction in drug CoGs by ~50% Improvement in patients' convenience and compliance upon potential commercialization RAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001).
2026-05-06 07:30:00
Novel vascularized, sensor-embedded cardiac organoid model will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair REHOVOT, Israel and RAMAT-GAN, Israel, May 6, 2026 /PRNewswire/ -- Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update
2026-04-25 02:38:52
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 502,390 shares, a growth of 2,578.7% from the March 31st total of 18,755 shares. Approximately 11.4% of the company's shares are short sold.
Frequently Asked Questions
-
What is the current Galmed Pharmaceuticals Ltd. (GLMD) stock price?
-
Galmed Pharmaceuticals Ltd.(NASDAQ:GLMD) stock price is $0.5135 in the last trading session. During the trading session, GLMD stock reached the peak price of $2.34 while $0.411 was the lowest point it dropped to. The percentage change in GLMD stock occurred in the recent session was 0.43% while the dollar amount for the price change in GLMD stock was $0.0.
-
GLMD's industry and sector of operation?
-
The NASDAQ listed GLMD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GLMD?
-
Liat Hayardeny | Chief Scientific Officer
Tali Gorfine | Medical Consultant
Allen Baharaff | Co-Founder, President, Chief Executive Officer & Chairman
Doron Cohen | Chief Financial Officer
Guy Nehemya | Chief Operating Officer & Data Protection Officer -
How many employees does GLMD have?
-
Number of GLMD employees currently stands at 6. GLMD operates from 16 Abba Hillel Road, Ramat Gan, TA 5250608, IL.
-
Link for GLMD official website?
-
Official Website of GLMD is: https://galmedpharma.com
-
How do I contact GLMD?
-
GLMD could be contacted at phone #972 3 693 8448 and can also be accessed through its website. GLMD operates from 16 Abba Hillel Road, Ramat Gan, TA 5250608, IL.
-
How many shares of GLMD are traded daily?
-
The average number of GLMD shares traded daily for last 3 months was 544.06K.
-
What is the market cap of GLMD currently?
-
The market value of GLMD currently stands at $2.81M with its latest stock price at $0.5135